The FDA cannot accept new fees or applications until the government shutdown is over.
HealthDay News — Due to the federal government shutdown, the U.S. Food and Drug Administration has only about five weeks of funding left to review new drug applications, according to Commissioner Scott Gottlieb, M.D.
To keep reviewing applications, the FDA has stretched those funds, which come from user fees paid by drug companies before the shutdown, Gottlieb said Monday on Twitter.
The FDA cannot accept new fees or applications until the shutdown is over, CNN reported. However, blood- and allergy-related products are not covered by the user fee program “so routine review activity ceased related to new products in these categories,” Gottlieb said. He also said the FDA has about three months of funding for medical devices.
Continue Reading
The partial shutdown began on Dec. 22 and on Jan. 12 became the longest government shutdown in U.S. history.
Enjoying our content?
Thanks for visiting Pulmonology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Pulmonology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.